Biotest AG : DGAP-News: Biotest AG: Biotest Announces Strategic Long-Term Manufacturing, Supply and License Agreement

DGAP-News: Biotest AG / Key word(s): Contract
Biotest AG: Biotest Announces Strategic Long-Term Manufacturing,
Supply and License Agreement

16.01.2013 / 10:00

/
PRESS RELEASE

Biotest Announces Strategic Long-Term Manufacturing, Supply and License
Agreement

- Manufacturing & Supply agreement

- License agreement for ADMA's Respiratory Syncytial Virus IGIV product
candidate for EU and selected countries

Dreieich/ Boca Raton, January 16, 2013 - Biotest announces, that Biotest
Pharmaceuticals Corp. (BPC), a wholly owned U.S. subsidiary of Biotest AG
(Dreieich, Germany) has entered into a strategic long-term manufacturing,
supply and license agreement with ADMA Biologics, Inc.(ADMA).

Under the terms of the agreement, ADMA has agreed to purchase exclusively
from BPC its worldwide requirements and product supply of RSV (Respiratory
Syncytial Virus) immune globulin (RI-002) manufactured from human plasma
containing RSV antibodies. The initial term of the agreement is for ten
years.

RI-002 is a specialty immune globulin for primary immune deficiency
patients, which is derived from human plasma containing high levels of
Respiratory Syncytial Virus (RSV) antibodies. For patients that are
immunocompromised naturally or medically due to an underlying illness or a
transplant, an RSV infection can present significant morbidity and
mortality. ADMA is currently preparing a pivotal Phase III clinical trial
in primary immune deficiency patients with this product in the United
States.

Also in connection with the manufacturing and supply agreement, ADMA has
out-licensed RI-002 to Biotest AG, to market and sell in Europe and
selected countries in North Africa and the Middle East. In return for this
license, Biotest AG will compensate ADMA upon the completion of certain
milestones as well as pay a royalty based on a percentage of sales of RSV
immune globulin in the territory. 'This specialty immune globulin product
will perfectly complement our hyper-immune globulin portfolio', Prof.
Gregor Schulz, CEO of Biotest comments this deal.

About ADMA's lead product candidate
ADMA's lead product candidate, RI-002 is a specialty plasma-derived,
polyclonal, Intravenous Immune Globulin, or IGIV, prepared with high levels
of antibodies against respiratory syncytial virus, or RSV. ADMA is pursuing
an indication for the use of this specialty IGIV product for treatment of
patients diagnosed with primary immunodeficiency disease, or PIDD.
Polyclonal antibodies are the primary component of IGIV products. PIDD is a
disorder that causes a person's immune system to not function properly.
PIDD is caused by hereditary or genetic defects and can affect anyone
regardless of age or gender.

About ADMA Biologics, Inc.
ADMA is a late-stage biotechnology company focused on developing specialty
immune globulin therapeutics and commercialization of human plasma. ADMA's
mission is to develop and commercialize plasma-derived, human immune
globulins targeted at niche patient populations some with unmet medical
needs. In addition, ADMA operates ADMA Bio Centers, a wholly-owned
subsidiary which is an FDA-licensed source plasma collection facility
located in Norcross, Georgia. Please visit www.admabiologics.com for more
information.

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest

Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
application of clinical immunology, haematology and intensive medicine. In
its Plasma Protein portfolio Biotest develops and markets immunoglobulins,
coagulation factors and albumins based on human blood plasma. These are
used for diseases of the immune and haematopoietic systems. Biotest also
researches into the development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and cancer of plasma cells. Biotest has
more than 1.600 employees worldwide. The preference shares of Biotest AG
are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: [phone],
e-mail: [e-mail]
fax: [phone]

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart

End of Corporate News

16.01.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [e-mail]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart

End of News DGAP News-Service

199187 16.01.2013